Approval · Notice of Compliance 5253 · 1995
IMITREX: Notice of Compliance 5253
Issued March 31, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5253
- Date
- March 31, 1995
- Company
- Glaxo Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised product monograph, new strength: 50 mg tablets for hepatic patients
- Therapeutic class
- 5-ht1 receptor agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMITREX | 02163764 | Cancelled Post Market |
| IMITREX | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 12 MG per ML
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB